Citations (100)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Amir Imran Faisal Hamdi, Soon Hin How, Mohammad Kaisarul Islam, Jonathan Chee Woei Lim & Johnson Stanslas. (2022) Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?. Expert Review of Anticancer Therapy 22:12, pages 1309-1323.
Read now
Read now
Ting Huang, Lijuan Tang, Huan Wang, Lu Lin & Jing Fu. (2021) Carbonic anhydrase 12 gene silencing reverses the sensitivity of paclitaxel in drug-resistant breast cancer cells. Bioengineered 12:2, pages 9806-9818.
Read now
Read now
Emilie Werbrouck, Julie Bastin, Diether Lambrechts, Annelies Verbiest, Thomas Van Brussel, Evelyne Lerut, Jean-Pascal Machiels, Vincent Verschaeve, Vincent Richard, Philip R. Debruyne, Brigitte Decallonne, Patrick Schöffski, Oliver Bechter, Pascal Wolter & Benoit Beuselinck. (2019) ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib. Acta Clinica Belgica 74:3, pages 180-188.
Read now
Read now
Mahmoud A. Elnaggar, Ramesh Subbiah, Dong Keun Han & Yoon Ki Joung. (2017) Lipid-based carriers for controlled delivery of nitric oxide. Expert Opinion on Drug Delivery 14:12, pages 1341-1353.
Read now
Read now
Piyush Bugde, Riya Biswas, Fabrice Merien, Jun Lu, Dong-Xu Liu, Mingwei Chen, Shufeng Zhou & Yan Li. (2017) The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opinion on Therapeutic Targets 21:5, pages 511-530.
Read now
Read now
Claudia Maria Hattinger, Marilù Fanelli, Elisa Tavanti, Serena Vella, Stefano Ferrari, Piero Picci & Massimo Serra. (2015) Advances in emerging drugs for osteosarcoma. Expert Opinion on Emerging Drugs 20:3, pages 495-514.
Read now
Read now
Camille Tlemsani, Olivier Huillard, Jennifer Arrondeau, Pascaline Boudou-Rouquette, Anatole Cessot, Benoit Blanchet, Audrey Thomas-Schoemann, Romain Coriat, Jean-Philippe Durand, Julie Giroux, Jérôme Alexandre & François Goldwasser. (2015) Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. Expert Opinion on Drug Metabolism & Toxicology 11:5, pages 785-794.
Read now
Read now
Limin Huang, Chaoquan Hu, Mélanie Di Benedetto, Rémi Varin, Jielin Liu, Li Wang, Jean-Pierre Vannier, Jian Jin, Anne Janin, He Lu & Hong Li. (2014) Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib. OncoTargets and Therapy 7, pages 2249-2255.
Read now
Read now
Yan Liu, Mingmao Chen, Zhipu Luo, Jingjing Lin & Ling Song. (2013) Investigation on the site-selective binding of bovine serum albumin by erlotinib hydrochloride. Journal of Biomolecular Structure and Dynamics 31:10, pages 1160-1174.
Read now
Read now
Marike Marjolijn van Beuge, Klaas Poelstra & Jai Prakash. (2012) Specific delivery of kinase inhibitors in nonmalignant and malignant diseases. Expert Opinion on Drug Delivery 9:1, pages 59-70.
Read now
Read now
Teruo Inamoto & Haruhito Azuma. (2011) Sorafenib increases endoplasmic reticulum (ER) stress in concert with vorinostat. Cancer Biology & Therapy 12:12, pages 1018-1018.
Read now
Read now
Articles from other publishers (89)
Chung-Pu Wu, Sung-Han Hsiao & Yu-Shan Wu. (2023) Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2. Drug Resistance Updates 71, pages 101011.
Crossref
Crossref
Stefanie A. Baril, Tomoka Gose & John D. Schuetz. (2023) How Cryo-EM Has Expanded Our Understanding of Membrane Transporters. Drug Metabolism and Disposition 51:8, pages 904-922.
Crossref
Crossref
Qingqing Pan, Yao Lu, Li Xie, Di Wu, Rong Liu, Wenxia Gao, Kui Luo, Bin He & Yuji Pu. (2023) Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy. Molecular Pharmaceutics 20:2, pages 829-852.
Crossref
Crossref
Wenjing Xu, Chunping Ye, Xin Qing, Shengli Liu, Xinyi Lv, Wenjun Wang, Xiaochen Dong & Yewei Zhang. (2022) Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Materials Today Bio 16, pages 100358.
Crossref
Crossref
Xian Zhu, Yinfang Zhang, Yafei Wu, Wenjing Diao, Guilong Deng, Qin Li & Chuanxing Wu. (2022) HMOX1 Attenuates the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib via Modulating the Expression of ABC Transporters. International Journal of Genomics 2022, pages 1-12.
Crossref
Crossref
Chung-Pu Wu, Cheng-Yu Hung, Megumi Murakami, Yu-Shan Wu, Chun-Ling Lin, Yang-Hui Huang, Tai-Ho Hung, Jau-Song Yu & Suresh Ambudkar. (2022) P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhibitor Ensartinib in Cancer Cells. Cancers 14:9, pages 2341.
Crossref
Crossref
Chung-Pu Wu, Megumi Murakami, Yu-Shan Wu, Chun-Ling Lin, Yan-Qing Li, Yang-Hui Huang, Tai-Ho Hung & Suresh V. Ambudkar. (2022) The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biomedicine & Pharmacotherapy 149, pages 112922.
Crossref
Crossref
B. Dudas, X. Decleves, S. Cisternino, D. Perahia & M.A. Miteva. (2022) ABCG2/BCRP transport mechanism revealed through kinetically excited targeted molecular dynamics simulations. Computational and Structural Biotechnology Journal 20, pages 4195-4205.
Crossref
Crossref
Massimo Serra, Claudia Maria Hattinger, Michela Pasello, Chiara Casotti, Leonardo Fantoni, Chiara Riganti & Maria Cristina Manara. (2021) Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?. Cells 10:9, pages 2461.
Crossref
Crossref
Ahmed Elfadadny, Hussein M. El-Husseiny, Amira Abugomaa, Rokaia F. Ragab, Eman A. Mady, Mohamed Aboubakr, Haney Samir, Ahmed S. Mandour, Amany El-Mleeh, Ali H. El-Far, Ayman H. Abd El-Aziz & Mohamed Elbadawy. (2021) Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives. Environmental Science and Pollution Research 28:36, pages 49447-49466.
Crossref
Crossref
Chung-Pu Wu, Yan-Qing Li, Ya-Chen Chi, Yang-Hui Huang, Tai-Ho Hung & Yu-Shan Wu. (2021) The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. International Journal of Molecular Sciences 22:17, pages 9440.
Crossref
Crossref
Furong Cheng, Qingqing Pan, Wenxia Gao, Yuji Pu, Kui Luo & Bin He. (2021) Reversing Chemotherapy Resistance by a Synergy between Lysosomal pH-Activated Mitochondrial Drug Delivery and Erlotinib-Mediated Drug Efflux Inhibition. ACS Applied Materials & Interfaces 13:25, pages 29257-29268.
Crossref
Crossref
Claudia Maria Hattinger, Maria Pia Patrizio, Leonardo Fantoni, Chiara Casotti, Chiara Riganti & Massimo Serra. (2021) Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. Cancers 13:12, pages 2878.
Crossref
Crossref
Chung-Pu Wu, Tai-Ho Hung, Sabrina Lusvarghi, Yi-Hsuan Chu, Sung-Han Hsiao, Yang-Hui Huang, Yu-Tzu Chang & Suresh V. Ambudkar. (2021) The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochemical Pharmacology 188, pages 114516.
Crossref
Crossref
Chung-Pu Wu, Cheng-Yu Hung, Sabrina Lusvarghi, Yen-Fu Chang, Sung-Han Hsiao, Yang-Hui Huang, Tai-Ho Hung, Jau-Song Yu & Suresh. V. Ambudkar. (2021) Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat. International Journal of Molecular Sciences 22:5, pages 2592.
Crossref
Crossref
Yuqi Yang, Zhuo-Xun Wu, Jing-Quan Wang, Qiu-Xu Teng, Zi-Ning Lei, Sabrina Lusvarghi, Suresh V. Ambudkar, Zhe-Sheng Chen & Dong-Hua Yang. (2021) OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Frontiers in Pharmacology 12.
Crossref
Crossref
Balázs Sarkadi, László Homolya & Tamás Hegedűs. (2020) The ABCG2/BCRP transporter and its variants – from structure to pathology. FEBS Letters 594:23, pages 4012-4034.
Crossref
Crossref
Brian B. Hasinoff & Daywin Patel. (2020) Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib. Cardiovascular Toxicology 20:4, pages 380-389.
Crossref
Crossref
Hiroaki Kinoh, Hitoshi Shibasaki, Xueying Liu, Tatsuya Yamasoba, Horacio Cabral & Kazunori Kataoka. (2020) Nanomedicines blocking adaptive signals in cancer cells overcome tumor TKI resistance. Journal of Controlled Release 321, pages 132-144.
Crossref
Crossref
Daniella Kovacsics, Anna Brózik, Borbála Tihanyi, Zsolt Matula, Adrienn Borsy, Nikolett Mészáros, Edit Szabó, Eszter Németh, Ábel Fóthi, Boglárka Zámbó, Dávid Szüts, György Várady, Tamás I. Orbán, Ágota Apáti & Balázs Sarkadi. (2020) Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells. Biochemical Pharmacology 175, pages 113865.
Crossref
Crossref
Chung-Pu Wu, Sung-Han Hsiao, Yang-Hui Huang, Lang-Cheng Hung, Yi-Jou Yu, Yu-Tzu Chang, Tai-Ho Hung & Yu-Shan Wu. (2020) Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Cancers 12:1, pages 195.
Crossref
Crossref
Guohua An & Marilyn E. Morris. 2020. Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy. Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy
67
96
.
Brayden D. Whitlock & Elaine M. Leslie. 2020. Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy. Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy
31
65
.
Chung-Pu Wu, Sabrina Lusvarghi, Jyun-Cheng Wang, Sung-Han Hsiao, Yang-Hui Huang, Tai-Ho Hung & Suresh V. Ambudkar. (2019) The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. International Journal of Molecular Sciences 21:1, pages 238.
Crossref
Crossref
Tijana Stanković, Jelena Dinić, Ana Podolski-Renić, Loana Musso, Sonja Stojković Burić, Sabrina Dallavalle & Milica Pešić. (2019) Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment. Current Medicinal Chemistry 26:33, pages 6074-6106.
Crossref
Crossref
Duval, Troquier, de Souza Silva, Demartines & Dormond. (2019) Diclofenac Potentiates Sorafenib-Based Treatments of Hepatocellular Carcinoma by Enhancing Oxidative Stress. Cancers 11:10, pages 1453.
Crossref
Crossref
Anne Hulin, Jeanick Stocco & Mohamed Bouattour. (2019) Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clinical Pharmacokinetics 58:8, pages 983-1014.
Crossref
Crossref
Chung-Pu Wu, Sabrina Lusvarghi, Jyun-Cheng Wang, Sung-Han Hsiao, Yang-Hui Huang, Tai-Ho Hung & Suresh V. Ambudkar. (2019) Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Molecular Pharmaceutics 16:7, pages 3040-3052.
Crossref
Crossref
Haizhou Liu, Shuyuan Wang, Shunheng Zhou, Qianqian Meng, Xueyan Ma, Xiaofeng Song, Lihong Wang & Wei Jiang. (2019) Drug Resistance-Related Competing Interactions of lncRNA and mRNA across 19 Cancer Types. Molecular Therapy - Nucleic Acids 16, pages 442-451.
Crossref
Crossref
Silvia Di Giacomo, Oscar Briz, Maria J. Monte, Laura Sanchez-Vicente, Lorena Abete, Elisa Lozano, Gabriela Mazzanti, Antonella Di Sotto & Jose J. G. Marin. (2019) Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps. Archives of Toxicology 93:3, pages 623-634.
Crossref
Crossref
Chung-Pu Wu & Sheng-Chieh Hsu. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
169
185
.
Maria R. Baer. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
67
88
.
Haneen Amawi, Hong-May Sim, Amit K. Tiwari, Suresh V. Ambudkar & Suneet Shukla. 2019. Drug Transporters in Drug Disposition, Effects and Toxicity. Drug Transporters in Drug Disposition, Effects and Toxicity
549
580
.
Shaocong Wu & Liwu Fu. (2018) Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Molecular Cancer 17:1.
Crossref
Crossref
Chung-Pu Wu, Ya-Ju Hsieh, Megumi Murakami, Shahrooz Vahedi, Sung-Han Hsiao, Ni Yeh, An-Wei Chou, Yan-Qing Li, Yu-Shan Wu, Jau-Song Yu & Suresh V. Ambudkar. (2018) Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochemical Pharmacology 155, pages 316-325.
Crossref
Crossref
SoHyun Bae, Ronilda D'Cunha, Jie Shao & Guohua An. (2018) Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice. European Journal of Pharmaceutical Sciences 117, pages 27-34.
Crossref
Crossref
Hiroto Hatakeyama, Takuya Fujiwara, Hiromi Sato, Ayu Terui & Akihiro Hisaka. (2018) Investigation of Metabolomic Changes in Sunitinib-Resistant Human Renal Carcinoma 786-O Cells by Capillary Electrophoresis-Time of Flight Mass Spectrometry. Biological and Pharmaceutical Bulletin 41:4, pages 619-627.
Crossref
Crossref
Elena Gazzano, Barbara Rolando, Konstantin Chegaev, Iris C. Salaroglio, Joanna Kopecka, Isabella Pedrini, Simona Saponara, Matteo Sorge, Ilaria Buondonno, Barbara Stella, Alessandro Marengo, Massimo Valoti, Mara Brancaccio, Roberta Fruttero, Alberto Gasco, Silvia Arpicco & Chiara Riganti. (2018) Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. Journal of Controlled Release 270, pages 37-52.
Crossref
Crossref
Chung-Pu Wu, Sung-Han Hsiao, Megumi Murakami, Ming-Jie Lu, Yan-Qing Li, Chia-Hung Hsieh, Suresh.V. Ambudkar & Yu-Shan Wu. (2017) Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Letters 409, pages 56-65.
Crossref
Crossref
Claudia M Hattinger, Marilù Fanelli, Elisa Tavanti, Serena Vella, Chiara Riganti, Piero Picci & Massimo Serra. (2017) Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?. Future Oncology 13:8, pages 673-677.
Crossref
Crossref
Joanna Kopecka, Gregory M. Rankin, Iris C. Salaroglio, Sally-Ann Poulsen & Chiara Riganti. (2016) P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors. Oncotarget 7:52, pages 85861-85875.
Crossref
Crossref
Bernhard Englinger, Daniela Lötsch, Christine Pirker, Thomas Mohr, Sushilla van Schoonhoven, Bernd Boidol, Charles-Hugues Lardeau, Melanie Spitzwieser, Pál Szabó, Petra Heffeter, Irene Lang, Margit Cichna-Markl, Bettina Grasl-Kraupp, Brigitte Marian, Michael Grusch, Stefan Kubicek, Gergely Szakács & Walter Berger. (2016) Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. Oncotarget 7:31, pages 50161-50179.
Crossref
Crossref
Sung-Han Hsiao, Yu-Jen Lu, Yan-Qing Li, Yang-Hui Huang, Chia-Hung Hsieh & Chung-Pu Wu. (2016) Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro. Molecular Pharmaceutics 13:6, pages 2117-2125.
Crossref
Crossref
Geetika Chakravarty, Aditi Mathur, Pallavi Mallade, Samantha Gerlach, Joniece Willis, Amrita Datta, Sudesh Srivastav, Asim B. Abdel-Mageed & Debasis Mondal. (2016) Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells. Biochimie 124, pages 53-64.
Crossref
Crossref
Wei Chen, Fang Wang, Xu Zhang, Jing Hu, Xiaokun Wang, Ke Yang, Liyan Huang, Meng Xu, Qingshan Li & Liwu Fu. (2016) Overcoming ABCG2-mediated multidrug resistance by a mineralized hyaluronan–drug nanocomplex. Journal of Materials Chemistry B 4:41, pages 6652-6661.
Crossref
Crossref
Gergely Szakács, Tamás Hegedűs & Balázs Sarkadi. 2016. ABC Transporters - 40 Years on. ABC Transporters - 40 Years on
341
355
.
Jing-Dun Xie, Yang Huang, Dong-Tai Chen, Jia-Hao Pan, Bing-Tian Bi, Kun-Yao Feng, Wan Huang & Wei-An Zeng. (2015) Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. PLOS ONE 10:12, pages e0143701.
Crossref
Crossref
Maricla Galetti, Pier Giorgio Petronini, Claudia Fumarola, Daniele Cretella, Silvia La Monica, Mara Bonelli, Andrea Cavazzoni, Francesca Saccani, Cristina Caffarra, Roberta Andreoli, Antonio Mutti, Marcello Tiseo, Andrea Ardizzoni & Roberta R. Alfieri. (2015) Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines. PLOS ONE 10:11, pages e0141795.
Crossref
Crossref
Chung-Pu Wu, Chia-Hung Hsieh, Sung-Han Hsiao, Shi-Yu Luo, Ching-Ya Su, Yan-Qing Li, Yang-Hui Huang, Chiun-Wei Huang & Sheng-Chieh Hsu. (2015) Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1. Molecular Pharmaceutics 12:11, pages 3885-3895.
Crossref
Crossref
Dwayne Koot & Duncan Cromarty. (2015) Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation. Drug Delivery and Translational Research 5:3, pages 257-267.
Crossref
Crossref
Haibo Wang, Zhengyao Qian, Hui Zhao, Xibo Zhang, Shuqiang Che, Hongtao Zhang, Haitao Shang, Jianheng Bao, Chengfei Hao, Junjian Liu & Zhonglian Li. (2015) CSN5 silencing reverses sorafenib resistance of�human hepatocellular carcinoma HepG2 cells. Molecular Medicine Reports.
Crossref
Crossref
Trevor J. Mathias, Karthika Natarajan, Suneet Shukla, Kshama A. Doshi, Zeba N. Singh, Suresh V. Ambudkar & Maria R. Baer. (2015) The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Investigational New Drugs 33:2, pages 300-309.
Crossref
Crossref
Joanna Kopecka, Ivana Campia, Andrea Jacobs, Andreas P. Frei, Dario Ghigo, Bernd Wollscheid & Chiara Riganti. (2015) Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget 6:9, pages 6776-6793.
Crossref
Crossref
Hiromi Sato, Sana Siddig, Miaki Uzu, Sayumi Suzuki, Yuki Nomura, Tatsuro Kashiba, Keisuke Gushimiyagi, Yuko Sekine, Tomoya Uehara, Yasushi Arano, Katsunori Yamaura & Koichi Ueno. (2015) Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. European Journal of Pharmacology 746, pages 258-266.
Crossref
Crossref
Yu Fukuda, Shangli Lian & John D. Schuetz. 2015. ABC Transporters and Cancer. ABC Transporters and Cancer
171
196
.
Csilla Hegedüs, Tamás Hegedüs & Balázs Sarkadi. 2015. Resistance to Targeted ABC Transporters in Cancer. Resistance to Targeted ABC Transporters in Cancer
209
244
.
Karthika Natarajan, Maria R. Baer & Douglas D. Ross. 2015. Resistance to Targeted ABC Transporters in Cancer. Resistance to Targeted ABC Transporters in Cancer
53
88
.
Martin Michaelis, Florian Rothweiler, Thomas Nerreter, Marijke van Rikxoort, Richard Zehner, Wilhelm G Dirks, Michael Wiese & Jindrich CinatlJrJr. (2014) Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression. BMC Research Notes 7:1.
Crossref
Crossref
Xiaoke Gu, Zhiguang Ren, Hui Peng, Sixun Peng & Yihua Zhang. (2014) Bifendate-chalcone hybrids: A new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein. Biochemical and Biophysical Research Communications 455:3-4, pages 318-322.
Crossref
Crossref
Jie Shao, John S. Markowitz, Di Bei & Guohua An. (2014) Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors. Journal of Pharmaceutical Sciences 103:12, pages 3810-3833.
Crossref
Crossref
Zhi-Xin Wang, Jiazhi Sun, Caitlin E. Howell, Qing-Yu Zhou, Zhi-Xu He, Tianxin Yang, Helen Chew, Wei Duan, Zhi-Wei Zhou, Jagat R. Kanwar & Shu-Feng Zhou. (2014) Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundamental & Clinical Pharmacology 28:5, pages 551-582.
Crossref
Crossref
Nagaraju Anreddy, Pranav Gupta, Rishil Kathawala, Atish Patel, John Wurpel & Zhe-Sheng Chen. (2014) Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance. Molecules 19:9, pages 13848-13877.
Crossref
Crossref
Isabella Pedrini, Elena Gazzano, Konstantin Chegaev, Barbara Rolando, Alessandro Marengo, Joanna Kopecka, Roberta Fruttero, Dario Ghigo, Silvia Arpicco & Chiara Riganti. (2014) Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells. Molecular Pharmaceutics 11:9, pages 3068-3079.
Crossref
Crossref
Jiexin Deng, Jie Shao, John S. Markowitz & Guohua An. (2014) ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors. Pharmaceutical Research 31:9, pages 2237-2255.
Crossref
Crossref
Suneet Shukla, Abdul Kouanda, Latoya Silverton, Tanaji T. Talele & Suresh V. Ambudkar. (2014) Pharmacophore Modeling of Nilotinib as an Inhibitor of ATP-Binding Cassette Drug Transporters and BCR-ABL Kinase Using a Three-Dimensional Quantitative Structure–Activity Relationship Approach. Molecular Pharmaceutics 11:7, pages 2313-2322.
Crossref
Crossref
Kamlesh Sodani, Atish Patel, Nagaraju Anreddy, Satyakam Singh, Dong-Hua Yang, Rishil J. Kathawala, Priyank Kumar, Tanaji T. Talele & Zhe-Sheng Chen. (2014) Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochemical Pharmacology 89:1, pages 52-61.
Crossref
Crossref
YUE-LI SUN, PRIYANK KUMAR, KAMLESH SODANI, ATISH PATEL, YIHANG PAN, MARIA R. BAER, ZHE-SHENG CHEN & WEN-QI JIANG. (2014) Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncology Reports 31:4, pages 1605-1612.
Crossref
Crossref
S Shukla, E E Chufan, S Singh, A P Skoumbourdis, K Kapoor, M B Boxer, D Y Duveau, C J Thomas, T T Talele & S V Ambudkar. (2014) Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein. Leukemia 28:4, pages 961-964.
Crossref
Crossref
Susan P.C. Cole. (2014)
Targeting Multidrug Resistance Protein 1 (MRP1,
ABCC1
): Past, Present, and Future
. Annual Review of Pharmacology and Toxicology 54:1, pages 95-117.
Crossref
Crossref
Michal Heger, Rowan F. van Golen, Mans Broekgaarden & Martin C. Michel. (2013) The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer. Pharmacological Reviews 66:1, pages 222-307.
Crossref
Crossref
Magdalena Buczek, Bernard Escudier, Ewa Bartnik, Cezary Szczylik & Anna Czarnecka. (2014) Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1845:1, pages 31-41.
Crossref
Crossref
Wei-Chien Huang, Yi-Ling Hsieh, Chao-Ming Hung, Pei-Hsuan Chien, Yu-Fong Chien, Lei-Chin Chen, Chih-Yen Tu, Chia-Hung Chen, Sheng-Chieh Hsu, Yueh-Ming Lin & Yun-Ju Chen. (2013) BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib. PLoS ONE 8:12, pages e83627.
Crossref
Crossref
Vivian M. Rumjanek, Raphael S. Vidal & Raquel C. Maia. (2013) Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR–CML cell lines?. Bioscience Reports 33:6.
Crossref
Crossref
L Xu, J-M Feng, J-X Li, J-M Zhu, S-S Song, L-J Tong, Y Chen, X-Y Yang, Y-Y Shen, F-L Lian, Y-P Li, D-H Lin, J Ding & Z-H Miao. (2013) Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks. Cell Death & Disease 4:11, pages e905-e905.
Crossref
Crossref
Chung-Pu Wu, Sung-Han Hsiao, Hong-May Sim, Shi-Yu Luo, Wei-Cherng Tuo, Hsing-Wen Cheng, Yan-Qing Li, Yang-Hui Huang & Suresh V. Ambudkar. (2013) Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1. Biochemical Pharmacology 86:7, pages 904-913.
Crossref
Crossref
Yu Fukuda, Kazumasa Takenaka, Alex Sparreboom, Satish B. Cheepala, Chung-Pu Wu, Sean Ekins, Suresh V. Ambudkar & John D. Schuetz. (2013) Human Immunodeficiency Virus Protease Inhibitors Interact with ATP Binding Cassette Transporter 4/Multidrug Resistance Protein 4: A Basis for Unanticipated Enhanced Cytotoxicity. Molecular Pharmacology 84:3, pages 361-371.
Crossref
Crossref
Ana Podolski-Renić, Milka Jadranin, Tijana Stanković, Jasna Banković, Sonja Stojković, Maria Chiourea, Ivana Aljančić, Vlatka Vajs, Vele Tešević, Sabera Ruždijić, Sarantis Gagos, Nikola Tanić & Milica Pešić. (2013) Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing. Cancer Chemotherapy and Pharmacology 72:3, pages 683-697.
Crossref
Crossref
Jasjeet Bhullar, Karthika Natarajan, Suneet Shukla, Trevor J. Mathias, Mariola Sadowska, Suresh V. Ambudkar & Maria R. Baer. (2013) The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions. PLoS ONE 8:8, pages e71266.
Crossref
Crossref
Brian B. Hasinoff, Daywin Patel & Xing Wu. (2012) The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin. Cardiovascular Toxicology 13:1, pages 33-47.
Crossref
Crossref
Hong-Ye Zhao, Hongjiang Wei & Xin Wang. (2013) The Reciprocal Interaction of Small Molecule Protein Kinase Inhibitors and ATP-Binding Cassette Transporters in Targeted Cancer Therapy. Journal of Cancer Research Updates 2:1.
Crossref
Crossref
Rupashree Sen, Karthika Natarajan, Jasjeet Bhullar, Suneet Shukla, Hong-Bin Fang, Ling Cai, Zhe-Sheng Chen, Suresh V. Ambudkar & Maria R. Baer. (2012) The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2. Molecular Cancer Therapeutics 11:9, pages 2033-2044.
Crossref
Crossref
Csilla Hegedüs, Krisztina Truta-Feles, Géza Antalffy, György Várady, Katalin Német, Csilla Özvegy-Laczka, György Kéri, László Őrfi, Gergely Szakács, Jeffrey Settleman, András Váradi & Balázs Sarkadi. (2012) Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance. Biochemical Pharmacology 84:3, pages 260-267.
Crossref
Crossref
Wen-jing Zhou, Xu Zhang, Chao Cheng, Fang Wang, Xiao-kun Wang, Yong-ju Liang, Kenneth Kin Wah To, Wang Zhou, Hong-bing Huang & Li-wu Fu. (2012) Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. British Journal of Pharmacology 166:5, pages 1669-1683.
Crossref
Crossref
F J Giles, H M Kantarjian, P D le Coutre, M Baccarani, F-X Mahon, R E Blakesley, N J Gallagher, K Gillis, S L Goldberg, R A Larson, A Hochhaus & O G Ottmann. (2011) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26:5, pages 959-962.
Crossref
Crossref
Toshiyuki Minami, Takashi Kijima, Yasushi Otani, Satoshi Kohmo, Ryo Takahashi, Izumi Nagatomo, Haruhiko Hirata, Mayumi Suzuki, Koji Inoue, Yoshito Takeda, Hiroshi Kida, Isao Tachibana & Atsushi Kumanogoh. (2012) HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter–Mediated Chemoresistance in Small Cell Lung Cancer. Molecular Cancer Therapeutics 11:4, pages 830-841.
Crossref
Crossref
Laleh Amiri-Kordestani, Agnes Basseville, Karen Kurdziel, Antonio Tito Fojo & Susan E. Bates. (2012) Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resistance Updates 15:1-2, pages 50-61.
Crossref
Crossref
Suneet Shukla, Zhe-Sheng Chen & Suresh V. Ambudkar. (2012) Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resistance Updates 15:1-2, pages 70-80.
Crossref
Crossref
Yi-fan Chen & Li-wu Fu. (2011) Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharmaceutica Sinica B 1:4, pages 197-207.
Crossref
Crossref
Tzu-Ching Kuo, Hsing-Pang Lu & Chuck C.-K. Chao. (2011) The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochemical Pharmacology 82:2, pages 184-194.
Crossref
Crossref